Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06500728 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Visual Involvement in Giant Cell Arteritis

Study acronym: Visu-GCA
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes. GCA is the most frequent vasculitis, an inflammation of vessels, in older adults. It involves large and medium-sized arteries and causes ischemic alterations such as stroke and blindness, through damage of extracranial arteries. The primary objective is to compare the frequency of the various ocular findings between the main alterations of arteritic and non-arteritic aetiology, such as Arteritic Anterior Ischemic Optic Neuropathy (A-AION) Vs. Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) or Central Retinal Artery Occlusion (CRAO) from GCA Vs. from other causes, through a comprehensive clinical and instrumental evaluation.
Trial Details
NCT Number NCT06500728
Lead Sponsor ASST Fatebenefratelli Sacco
Conditions
(from sponsor)		 Giant Cell Arteritis, Visual Impairment, Central Retinal Artery Occlusion, Anterior Ischemic Optic Neuropathy, Paracentral Acute Middle Maculopathy, Posterior Ischemic Optic Neuropathy, Retinal Ischemia, Blindness +1 more
Related terms Blindness, Giant Cell Arteritis, Optic Neuropathy, Ischemic, Retinal Artery Occlusion, Vision Disorders
Enrollment 762 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov